* Fda advisory committee votes 12 to 2 that benefits of acadia pharmaceuticals' nuplazid(tm) (pimavanserin) for the treatment of psychosis associated with parkinson's disease outweigh the risks Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
Read more
No comments:
Post a Comment